RATIONALE: Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, improves exacerbation rates, lung function and patient-reported outcomes in patients with inadequately controlled eosinophilic asthma and > _1 exacerbation in the prior year. Rates of complete exacerbation response, defined as experiencing zero exacerbations through 52wks, are previously unreported. METHODS: Data were pooled from two 52-week placebo-controlled phase 3 trials of IV reslizumab (3mg/kg Q4W) (Castro, 2015). Differences between reslizumab and placebo in proportions of patients with zero exacerbations during the treatment period are reported for the overall population and subgroups of patients with early improvement by 16wks in ACQ-6 (minimal important difference [MID] -0.5) and/or FEV 1 (MID +100mL). RESULTS: Of the 953 patients included in the trials (reslizumab n5477; placebo n5476), 68% of reslizumab patients and 50% of placebo patients had zero exacerbations through 52wks. The proportions of patients who had zero exacerbations increased among those with early improvement in ACQ-6 (73%) or FEV 1 (73%) in the reslizumab group, but not in the placebo group (51%; 46%). Reslizumab-treated patients who showed early improvement in both ACQ-6 and FEV 1 had a complete exacerbation response rate of 77% versus 45% for placebo. This contrasts with rates of complete exacerbation response for reslizumab-treated patients not achieving early improvement in FEV 1 : 59% or early improvement in ACQ-6: 53%. CONCLUSIONS: More patients receiving reslizumab versus placebo had zero exacerbations through 52wks. Rates of complete exacerbation response were greatest among patients with early treatment response to reslizumab, as indicated by clinically significant improvement in ACQ-6 and/or FEV 1 at 16wks.
Rochester Regional Health, Rochester, NY, 3 University of Rochester School of Medicine & Dentistry, Rochester, NY. RATIONALE: Reslizumab, a humanized anti-interleukin-5 monoclonal antibody, improves exacerbation rates, lung function and patient-reported outcomes in patients with inadequately controlled eosinophilic asthma and > _1 exacerbation in the prior year. Rates of complete exacerbation response, defined as experiencing zero exacerbations through 52wks, are previously unreported. METHODS: Data were pooled from two 52-week placebo-controlled phase 3 trials of IV reslizumab (3mg/kg Q4W) (Castro, 2015) . Differences between reslizumab and placebo in proportions of patients with zero exacerbations during the treatment period are reported for the overall population and subgroups of patients with early improvement by 16wks in ACQ-6 (minimal important difference [MID] -0.5) and/or FEV 1 (MID +100mL). RESULTS: Of the 953 patients included in the trials (reslizumab n5477; placebo n5476), 68% of reslizumab patients and 50% of placebo patients had zero exacerbations through 52wks. The proportions of patients who had zero exacerbations increased among those with early improvement in ACQ-6 (73%) or FEV 1 (73%) in the reslizumab group, but not in the placebo group (51%; 46%). Reslizumab-treated patients who showed early improvement in both ACQ-6 and FEV 1 had a complete exacerbation response rate of 77% versus 45% for placebo. This contrasts with rates of complete exacerbation response for reslizumab-treated patients not achieving early improvement in FEV 1 : 59% or early improvement in ACQ-6: 53%. CONCLUSIONS: More patients receiving reslizumab versus placebo had zero exacerbations through 52wks. Rates of complete exacerbation response were greatest among patients with early treatment response to reslizumab, as indicated by clinically significant improvement in ACQ-6 and/or FEV 1 at 16wks. Long-term data on intra-individual variability in EOS in large cohorts of eosinophilic asthma patients are limited. Reslizumab, an anti-IL5 monoclonal antibody, reduces asthma exacerbation risk and improves lung function and patient-reported outcomes in patients with uncontrolled eosinophilic asthma. This post-hoc analysis assessed the variability in EOS levels among participants in multicenter Phase 3 studies of IV reslizumab who received placebo for up to 52 weeks (wks). METHODS: Pooled data from study participants with inadequately controlled asthma and screening blood EOS count > _400/mL were analyzed. Shifts between absolute EOS count categories and magnitudes of changes in EOS levels are described in patients who received placebo. RESULTS: Among patients receiving placebo (N5476; categories of baseline [day of randomization] EOS <400/mL n5124, > _400-<800/mL n5218, > _800-<1200/mL n592, > _1200/mL n542), overall baseline [mean6SE] EOS were 655629/mL, decreased by -119626/mL from baseline at 16wks, and then stabilized (change from baseline at 52wks -117631/mL). Proportions of patients with shifts to a new EOS category after 4wks increased with increasing baseline EOS levels (<400/mL 47%, > _400-<800/mL 47%, > _800-<1200/mL 67%, > _1200/mL 67%) with similar proportions at 16wks and 52wks. The proportion with blood EOS <400/mL at any post-baseline time point was greater with baseline EOS <800 vs > _800. CONCLUSIONS: Mean EOS counts decreased slightly by 16wks then stabilized over 52wks in placebo-treated patients. High intra-individual variability in EOS counts in this population of eosinophilic asthma patients was observed.
